Clofibrate And Niacin In Coronary Heart Disease
Notes for this study:
|Number of Subjects
In a study randomizing subjects to one of six groups, one of which was 3g of niacin daily (an active control of clofibrate), in men between the ages of 30-64 who experienced at least one myocardial infarction, supplementation of niacin reduced cholesterol and triglycerides relative to placebo throughout the study period and for five years followup.
Niacin appeared to reduce overall cardiovascular events, but did not reduce overall mortality relative to placebo.
Niacin was associated with a higher dropout rate than other groups, thought to be due to the niacin flush.